IP Library Granted Patent US 11,697,796
Granted Patent B2
US 11,697,796 · App. 16/480,025 · Granted Jul 11, 2023

Media and methods for enhancing the survival and proliferation of stem cells

Inventors: Adam Hirst (Vancouver, CA); Arwen Hunter (Vancouver, CA); Melanie Kardel (Vancouver, CA); Wing Chang (Vancouver, CA)
Assignee: STEMCELL TECHNOLOGIES CANADA INC.
C12N5/0606C12N5/0696C12N2500/36C12N2501/115C12N2501/15C12N2501/727C12N2501/999C12N2533/90
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,697,796
App. No.
16/480,025
Granted
Jul 11, 2023
Kind
B2
Abstract

The present disclosure relates to improved supplements, culture media and methods for enhancing the survival or proliferation of mammalian stem cells. In particular, adding a lipid supplement, such as a lipid-enriched carrier (e.g. a lipid-enriched albumin), to the culture medium may enhance the survival and/or proliferation of the stem cells by at least 5% to 65% as compared to a culture medium that does not contain the lipid supplement.

Claims (16)

1. A cloning supplement comprising one or more small molecule inhibitors and two or more lipids in the presence of a carrier, wherein

the carrier is an agent, substance, composition or complex that transports some or all of the two or more lipids to a mammalian pluripotent stem cell,

the two or more lipids comprise oleic acid and palmitic acid,

the amount of each alpha-linolenic acid and/or arachidonic acid is less than 300 μg per gram of carrier, and

wherein the survival or proliferation of mammalian pluripotent stem cells is enhanced in a culture medium containing the supplement as compared to a culture medium that does not contain the supplement.

2. The cloning supplement according to claim 1 , further comprising one or more of Mead's acid, arachidic acid, palmitoleic acid, myristic acid, myristoleic acid, linoleic acid, stearic acid, alpha-linolenic acid, arachidonic acid, cholesterol, and DL-alpha-tocopheryl.

3. The cloning supplement according to claim 1 , wherein the cloning efficiency is 5% to 65%.

4. The cloning supplement according to claim 1 , wherein the pluripotent stem cells are ES cells or iPS cells.

5. The cloning supplement according to claim 1 , wherein the carrier is an agent for transporting the one or more lipids to the one or more mammalian pluripotent stem cells.

6. The cloning supplement according to claim 1 , wherein the carrier is an albumin, a liposome, an extracellular vesicle, an exosome, a nanostructured lipid carrier, or a cyclodextrin.

7. The cloning supplement according to claim 6 , wherein the albumin is human.

8. The cloning supplement according to claim 6 , wherein the albumin is recombinant.

9. The cloning supplement according to claim 1 , wherein at least some of the one or more lipids are bound to the carrier.

10. The cloning supplement according to claim 1 , wherein a concentration of the one or more lipids ranges from 1 ng/ml to 35 μg/ml.

11. The cloning supplement according to claim 1 , wherein the cloning supplement is diluted in the mammalian pluripotent stem cell culture medium.

12. The cloning supplement according to claim 1 , wherein the one or more small molecule inhibitors is Thiazovivin, Y-27632, CHIR99021, S8202190, MI-7, Necrostatin-1, NS3694, Wnt-C59, NSCI, or BIPV5.

Assignments (2)
SECURITY INTEREST Recorded Jun 30, 2022
From: STEMCELL TECHNOLOGIES CANADA INC.
To: HSBC BANK CANADA
Reel/Frame 060544/0596 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 31, 2020
From: HIRST, ADAM; KARDEL, MELANIE; CHANG, WING; HIATT, MICHAEL; JERVIS, ERIC; HUNTER, ARWEN
To: STEMCELL TECHNOLOGIES CANADA INC.
Reel/Frame 051686/0558 →
Continuity (4)
Provisional Application 62608875 · Dec 21, 2017
Provisional Application 62518776 · Jun 13, 2017
Provisional Application 62449413 · Jan 23, 2017
Related Publication 20200017825A1 · Jan 16, 2020